OBJECTIVE: The aims of this study were to evaluate the prevalence of metabolic syndrome (MS) in a cohort of pregnant women with a wide range of glucose tolerance, pre-pregnancy risk factors for MS during pregnancy and the effects of MS in the occurrence of adverse perinatal outcomes. RESEARCH DESIGN AND METHODS: One hundred and thirty six women with positive screening for gestational diabetes (GDM) were classified by two diagnostic methods: glycaemic profile and 100 g oral glucose tolerance test (OGTT) as normoglycaemic, mild gestational hyperglycaemic, GDM, and overt GDM. Markers of insulin resistance were measured between 24-28 and 36th week of gestation, and 6 weeks after delivery. RESULTS: The prevalence of MS was 0; 20.0; 23.5 and 36.4% in normoglycaemic, mild hyperglycaemic, GDM and overt GDM groups, respectively. Previous history of GDM with or without insulin use, body mass index (BMI) > or = 25, hypertension, family history of diabetes in first-degree relatives, non-Caucasian ethnicity, history of prematurity and polyhydramnios were statistically significant pre-pregnancy predictors for MS in the index pregnancy, that by its turn increased the occurrence of adverse perinatal outcomes (p = 0.01). CONCLUSIONS: The prevalence of MS increases with the worsening of glucose tolerance and is an independent predictor of adverse perinatal outcomes; impaired glycaemic profile identifies pregnancies with important metabolic abnormalities that are linked to the occurrence of adverse perinatal outcomes even in the presence of a normal OGTT, in patients that are not currently classified as having GDM. Copyright (c) 2008 John Wiley & Sons, Ltd.
OBJECTIVE: The aims of this study were to evaluate the prevalence of metabolic syndrome (MS) in a cohort of pregnant women with a wide range of glucose tolerance, pre-pregnancy risk factors for MS during pregnancy and the effects of MS in the occurrence of adverse perinatal outcomes. RESEARCH DESIGN AND METHODS: One hundred and thirty six women with positive screening for gestational diabetes (GDM) were classified by two diagnostic methods: glycaemic profile and 100 g oral glucose tolerance test (OGTT) as normoglycaemic, mild gestational hyperglycaemic, GDM, and overt GDM. Markers of insulin resistance were measured between 24-28 and 36th week of gestation, and 6 weeks after delivery. RESULTS: The prevalence of MS was 0; 20.0; 23.5 and 36.4% in normoglycaemic, mild hyperglycaemic, GDM and overt GDM groups, respectively. Previous history of GDM with or without insulin use, body mass index (BMI) > or = 25, hypertension, family history of diabetes in first-degree relatives, non-Caucasian ethnicity, history of prematurity and polyhydramnios were statistically significant pre-pregnancy predictors for MS in the index pregnancy, that by its turn increased the occurrence of adverse perinatal outcomes (p = 0.01). CONCLUSIONS: The prevalence of MS increases with the worsening of glucose tolerance and is an independent predictor of adverse perinatal outcomes; impaired glycaemic profile identifies pregnancies with important metabolic abnormalities that are linked to the occurrence of adverse perinatal outcomes even in the presence of a normal OGTT, in patients that are not currently classified as having GDM. Copyright (c) 2008 John Wiley & Sons, Ltd.
Authors: Carlos Antonio Negrato; Renan M Montenegro; Rosiane Mattar; Lenita Zajdenverg; Rossana P V Francisco; Belmiro Gonçalves Pereira; Mauro Sancovski; Maria Regina Torloni; Sergio A Dib; Celeste E Viggiano; Airton Golbert; Elaine C D Moisés; Maria Isabel Favaro; Iracema M P Calderon; Sonia Fusaro; Valeria D D Piliakas; José Petronio L Dias; Marilia B Gomes; Lois Jovanovic Journal: Diabetol Metab Syndr Date: 2010-04-24 Impact factor: 3.320
Authors: Rafael Bottaro Gelaleti; Débora Cristina Damasceno; Paula Helena Ortiz Lima; Daisy Maria Favero Salvadori; Iracema de Mattos Paranhos Calderon; José Carlos Peraçoli; Marilza Vieira Cunha Rudge Journal: Diabetol Metab Syndr Date: 2015-01-15 Impact factor: 3.320
Authors: Rafael B Gelaleti; Débora C Damasceno; Daisy M F Salvadori; João Paulo C Marcondes; Paula H O Lima; Glilciane Morceli; Iracema M P Calderon; Marilza V C Rudge Journal: Diabetol Metab Syndr Date: 2015-04-02 Impact factor: 3.320